Business Context and Reporting Period
Company: Entero Therapeutics, Inc. (formerly First Wave Biopharma, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Entero is a biotechnology company developing non-systemic therapies for gastrointestinal diseases, primarily focused on Adrulipase. On September 30, 2025, the Company acquired Grid AI Corp., an AI-driven energy technology platform, diversifying its operations. The Company is currently in the process of divesting its ImmunogenX (IMGX) subsidiary, which has been classified as held-for-sale and discontinued operations.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1,152,809) | $(2,580,971) | $(3,410,700) | $(5,821,067) |
| Net Loss (Continued Ops) | $(970,856) | $(1,895,252) | $(2,593,892) | $(3,820,307) |
| Loss from Discontinued Ops | $(181,953) | $(685,719) | $(816,808) | $(2,000,760) |
| Operating Expenses | $934,787 | $1,892,607 | $2,395,037 | $14,417,763 |
| Cash and Equivalents (End of Period) | $2,517,218 (as of Sept 30, 2025) | |||
| Net Cash Used in Operating Activities | N/A | $(1,729,201) | $(9,046,305) | |
| Net Cash Provided by Financing Activities | N/A | $3,725,000 | $5,613,152 |
Material Changes vs. Prior Period
- Acquisition of Grid AI: On September 30, 2025, Entero acquired Grid AI Corp. for approximately $27.1 million in equity consideration (Common Stock and Series H Preferred Stock). This added $24.1 million in goodwill and significant intangible assets (developed technology, customer relationships) to the balance sheet.
- Divestiture of IMGX: The Company is executing a Rescission Agreement to divest its ImmunogenX (IMGX) subsidiary. Assets and liabilities of IMGX (approx. $83.2M assets, $23.7M liabilities) are classified as held-for-sale. This resulted in discontinued operations losses of $0.8M for the nine months ended Sept 30, 2025.
- Expense Reduction: Total operating expenses decreased significantly year-over-year. For the nine months ended Sept 30, 2025, expenses were $2.4M compared to $14.4M in the prior year. This reduction is primarily due to the absence of non-cash expenses related to the IMGX merger (financial advisor fees, stock-based compensation) and reduced headcount.
- Debt and Liquidity: The Company drew $700,000 on a new $2.0M revolving line of credit in January 2025. Cash balances increased from $163,476 at year-end 2024 to $2.5M at Sept 30, 2025, driven by financing activities and the cash acquired in the Grid AI deal.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for one year from the filing date. The Company has an accumulated deficit of $205.8M and requires significant additional capital to fund operations and development.
- Nasdaq Compliance: The Company received a Staff Determination Letter from Nasdaq stating the Grid AI transaction constitutes a "Change of Control," requiring the post-transaction entity to satisfy initial listing requirements. Failure to comply could result in delisting. The Company is currently in compliance with minimum stockholders' equity requirements.
- Legal Proceedings:
- EGS Lawsuit: Ellenoff Grossman & Schole LLP sued for unpaid legal fees of $749,301. The Company has accrued this amount and is negotiating a settlement.
- Asymchem Lawsuit: Asymchem, Inc. filed a suit for $171,219 in unpaid services. A motion for summary judgment is pending.
- IMGX Debt Settlement: A settlement was reached with Mattress Liquidators, Inc. regarding IMGX debt, with former shareholders responsible for the majority of the payment.
- Outlook: The Company plans to continue developing Adrulipase in 2026. It is actively pursuing a Qualified Public Equity Offering (QPEO) of at least $5.0M as a condition of its revolving loan agreement.
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to secure the necessary capital to fund operations beyond the next 12 months given the substantial doubt expressed in the filing.
- Nasdaq Listing Risk: Monitor the outcome of the "Change of Control" determination and the Company's ability to meet initial listing requirements to avoid delisting.
- IMGX Divestiture Completion: Confirm the closing of the Rescission Agreement to ensure the Company is fully released from IMGX liabilities (approx. $9.3M secured debt remains with IMGX).
- Grid AI Integration: Assess the financial performance and integration progress of the newly acquired Grid AI subsidiary, which was acquired on the last day of the reporting period.
- Legal Accruals: Review the status of the EGS and Asymchem lawsuits to ensure the accrued liabilities ($749k and $171k) are accurate and settlements are finalized.